STOCK TITAN
  1. Home
  2. News
  3. MRNS

Marinus Pharmaceuticals Inc - MRNS STOCK NEWS

Welcome to our dedicated news page for Marinus Pharmaceuticals (Ticker: MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marinus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marinus Pharmaceuticals's position in the market.

News
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) reported a preliminary net product revenue of $6.5-6.7 million for Q4 2023 and $19.5-19.7 million for full year 2023. The projected full year 2024 U.S. ZTALMY net product revenue is $32-34 million. Over 90% of patients for the RAISE trial are enrolled, and TrustTSC trial enrollment is over 70%. The cash runway is projected into Q4 2024 with $150.3 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
-
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (MRNS) granted 74,650 non-qualified stock options and 2,500 restricted stock units to four new employees. The stock options have an exercise price of $7.97 per share and will vest in 36 equal monthly installments. The restricted stock units will vest in three equal installments over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
News
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced the publication of two-year open-label extension Marigold trial data of ZTALMY® (ganaxolone) oral suspension CV in patients with CDKL5 deficiency disorder (CDD). The company also revealed the acceptance of seven abstracts for presentation at the upcoming American Epilepsy Society (AES) 2023 Annual Meeting, showcasing the potential of ganaxolone in the treatment of refractory seizure disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
News
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that CEO Scott Braunstein, M.D. will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference. The event will be held on November 28 at 12:55 p.m. Eastern Time. A webcast link is available on Marinus’ website, with a replay accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
conferences
-
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
MRNS: Marinus Pharmaceuticals Announces Grant of Inducement Awards to New Employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
News
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) reported Q3 net product revenue of $5.4 million, with 2023 net product revenue guidance increased to between $18.5 and $19 million. Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus, with topline data anticipated Q2 2024. The company also initiated the Marinus Access Program to expand global availability of ZTALMY, and has a cash runway projected into Q4 2024 with $176.4 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
earnings
News
Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY® (ganaxolone) Oral Suspension CV
Rhea-AI Summary
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has announced the initiation of the Marinus Access Program, a global managed access program for ZTALMY® (ganaxolone) oral suspension CV. This program will enable physicians to request ZTALMY for eligible patients with seizures associated with CDKL5 deficiency disorder (CDD) in geographies where the product is not commercially available and as supported by local regulatory requirements. The U.S. Food and Drug Administration and the European Commission have approved ZTALMY for appropriate patients with CDKL5 deficiency disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
none
-
News
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Marinus Pharmaceuticals plans to release financial results for Q3 2023 on November 7, 2023. A conference call will be held at 8:30 a.m. Eastern Time on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
earnings
-
News
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Marinus Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Marinus Pharmaceuticals CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
Stock MRNS logo
Marinus Pharmaceuticals Inc

Nasdaq:MRNS

MRNS Rankings

#4448 Ranked by Market Cap
#1099 Ranked by Stock Gains
N/A Ranked by Dividends

MRNS Stock Data

413.08M
42.76M
1.57%
98.62%
6.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Radnor

About MRNS

marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides